Back to News
Market Impact: 0.1
Better Pharma ETF: iShares IHE vs. State Street XPH
Source: Nasdaq
Healthcare & BiotechInvestor Sentiment & Positioning
The iShares U.S. Pharmaceuticals ETF is more concentrated than the State Street SPDR S&P Pharmaceuticals ETF, with Eli Lilly representing 23.63% of the iShares portfolio. The article provides no further portfolio weights or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?
- Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
- Better Pharma ETF: iShares IHE vs. State Street XPH
- Twist Bioscience CEO Emily Leproust sells $919,373 in stock
- Stocks saw new highs and big declines: How the volatile AI trade moved last week's market
- Cerebras Is About as Big as Nvidia's Data Center Business Was Nearly a Decade Ago. The Similarities Mostly End There.